Article

Economic crisis hits home

Last week, two major cardiovascular healthcare companiesGE Healthcare and Philips Healthcarereported losses for the 2008 fiscal third quarter. In unveiling their shaky financials, execs from both vendors cited trouble in the credit markets as a reason for problems they face in the U.S. healthcare sector, as hospitals are finding it difficult to get funding for capital equipment purchases.

Senate probes TCT over fiscal ties to industry

Sens. Charles Grassley, R-Iowa, and Herb Kohl, D-Wis., have requested that the Cardiovascular Research Foundation (CRF), which sponsors Transcatheter Cardiovascular Therapeutics (TCT), and Columbia University, reveal how medical devicemakers have promoted their products throughout the symposiums sessions.

Boston Scientific losses narrow in Q3; despite falling stent sales

Boston Scientific has reported its financial results for the 2008 third quarter, which ended Sept. 30, as well as its guidance for net sales for the fourth quarter of this year.

Lehman Brothers crisis incites Boston Scientific stock sell-off

The bankruptcy of Lehman Brothers Holdings has taken a toll on Boston Scientific, forcing the founders to sell approximately 13 million shares.

Boston Scientific sees losses narrow in Q3, despite falling stent sales

Boston Scientific has reported its financial results for the 2008 third quarter, which ended September 30, as well as its guidance for net sales for the fourth quarter of this year.

Government probes FDA actions in Actavis recalls

The House Energy and Commerce Committee is investigating alleged FDA shortcomings to request more information about Actavis recalls, including withdrawal of all products from its Little Falls, N.J. plant.

HORIZONS AMI data will likely lead to wider bivalirudin usage in acute MI

WASHINGTONAfter one year, use of bivalirudin in MI patients, who receive angioplasty, resulted in significantly lower rates of all-cause death, death from cardiac causes, and major bleeding, compared to the standard drug therapy of heparin and glycoprotein IIb/IIIa inhibitors, according to the HORIZONS AMI trial presented Wednesday at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

HORIZONS AMI finds DES more effective, as safe as BMS at one year

WASHINGTONAfter one year, use of a drug-eluting stent (DES) in heart attack patients demonstrated significantly reduced rates of target lesion revascularization and binary angiographic restenosis when compared to the use of a bare metal stent (BMS), according to the HORIZONS AMI trial presented Wednesday at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Around the web

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Trimed Popup
Trimed Popup